文献速递结核与非结核分枝杆菌

氯法齐明在利福平耐药结核病患儿中的药代动力学与安全性

Pharmacokinetics and Safety of Clofazimine in Children With Rifampicin-Resistant Tuberculosis.
PubMed 文献 · J Infect Dis · 2025-01-01

该研究纳入20例18岁以下耐多药/利福平耐药结核病患儿,按体重给予氯法齐明,在基线及第2周、第16周进行稀疏和半密集药代动力学采样,并与成人目标周AUC比较。患儿氯法齐明周AUC中位数162.94 mg×h/L,高于耐多药/利福平耐药结核病成人目标周AUC 111.79 mg×h/L;未发生严重或≥3级心脏事件,氯法齐明浓度每升高1 µg/L,QT间期增加0.02毫秒。

要点

  • 患儿氯法齐明周AUC中位数162.94 mg×h/L,高于耐多药/利福平耐药结核病成人目标值111.79 mg×h/L
  • 未发生严重或≥3级心脏事件,QT间期随氯法齐明浓度升高而延长
  • 1例严重不良事件(丙氨酸转移酶升高)导致氯法齐明暂时停用

核心结论

  • 儿童使用所给氯法齐明剂量达到的暴露显著高于接受标准氯法齐明剂量的成人。
  • 较高的氯法齐明暴露与QT间期延长相关,可能对儿童构成不必要的风险,尤其与其它延长QT间期的药物联用时。

研究设计与样本

  • 研究纳入年龄小于18岁的耐多药/利福平耐药结核病患儿。
  • 氯法齐明按体重给药,在基线及第2周和第16周完成稀疏和半密集药代动力学采样。
  • 将患儿氯法齐明周AUC与耐多药/利福平耐药结核病成人每日100 mg氯法齐明及麻风病成人每日100 mg氯法齐明的目标周AUC(分别为60.87 mg×h/L和111.79 mg×h/L)进行比较。
  • 安全性监测包括QT间期延长测量和实验室评估。
  • 共纳入20例患儿,年龄中位数6.0岁(IQR,1.6-14.4),其中6例(30%)为男性。

主要发现

  • 患儿氯法齐明周AUC中位数为162.94(IQR,130.06-263.95),比耐多药/利福平耐药结核病成人目标周AUC(111.79;IQR,81.9-151.9)高25%以上。
  • 未发生严重或≥3级心脏事件。
  • 氯法齐明浓度每升高1 µg/L,QT间期增加0.02毫秒。
  • 1例严重不良事件(丙氨酸转移酶升高)导致氯法齐明暂时停用。

关键数值与推荐

  • 耐多药/利福平耐药结核病成人每日100 mg氯法齐明的目标周AUC为60.87 mg×h/L。
  • 麻风病成人每日100 mg氯法齐明的目标周AUC为111.79 mg×h/L。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We described the pharmacokinetics and safety of clofazimine in children treated for multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB). METHODS: Children aged <18 years were eligible. Clofazimine was administered by weight-based dosing. Sparse and semi-intensive pharmacokinetic sampling was completed at baseline and weeks 2 and 16. Clofazimine weekly area under the concentration time-curve (wAUC) was compared with the target wAUC (60.87 mg × h/L and 111.79 mg × h/L) in adults receiving clofazimine (100 mg) daily for MDR/RR-TB and leprosy, respectively. Safety monitoring included measurement of QT interval prolongation and laboratory assessment. RESULTS: Twenty children were included: median age was 6.0 years (IQR, 1.6-14.4); 6 (30%) were male. Median clofazimine wAUC was 162.94 (IQR, 130.06-263.95), >25% higher than the target adult wAUC in adults with MDR/RR-TB (111.79; IQR, 81.9-151.9). No serious or grade ≥3 cardiac events occurred. There was a QT interval increase of 0.02 milliseconds for every 1-µg/L increase in clofazimine concentration. One severe adverse event (elevated alanine transferase) led to temporary withdrawal of clofazimine. CONCLUSIONS: The clofazimine doses used achieved substantially higher exposures in children than adults receiving standard clofazimine doses. The association of higher clofazimine exposures and QT interval prolongation may pose unnecessary risk to children, particularly in combination with other QT-prolonging drugs. CLINICAL TRIALS REGISTRATION: South African National Clinical Trials Register (https://sanctr.samrc.ac.za/; DOH-27-0620-6415).

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hughes JA, Solans BP, Garcia-Prats AJ, et al. Pharmacokinetics and Safety of Clofazimine in Children With Rifampicin-Resistant Tuberculosis. J Infect Dis. 2025. PMID: 39932891. doi:10.1093/infdis/jiaf057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。